UCB has three products currently in phase III which are due to produce pivotal results in the next few years: brivaracetam for epilepsy, lupus treatment epratuzumab and romosozumab for osteoporosis.

United Community Banks (UCB) is headquartered in Greenville, and is in the Finance sector. The stock has seen a price change of 2.04% since the start of the year. The bank holding company is ...

Belgian pharmaceutical company UCB is dropping its development of minzasolmin in patients with Parkinson's' disease after the ORCHESTRA study failed to meet its primary and secondary endpoints.

UCB puts the performance of its drug down to its ability to inhibit both IL-17A and IL-17F, while Cosentyx only targets IL-17A . It says there is evidence to suggest that IL-17F is also a key ...

UCB emerged as a major biopharmaceutical player in the 1990s with the development of blockbuster drugs Zyrtec and Keppra. Throughout the 1990s and early 2000s, UCB transformed from a hybrid pharma ...

UCB’s Bimzelx is firmly on physicians’ radars, with Spherix Global Insights finding that awareness of the drug was tracking ahead of AbbVie’s Rinvoq and Skyrizi three months into its ...